Michele Stanislaw Milella

Dr. Michele Stanislaw Milella

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2023 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
MMMichele Stanislaw Milella
Michele Stanislaw Milella
GDGinevra D'Ottavio
Ginevra D'Ottavio
SPSilvana De Pirro
Silvana De Pirro
MBMassimo Barra
Massimo Barra
DCDaniele Caprioli
Daniele Caprioli
ABAldo Badiani
Aldo Badiani
Heroin is an opioid agonist commonly abused for its rewarding effects. Since its synthesis at the end of the nineteenth century, its popularity as a recreational drug has ebbed and flowed. In the last three decades, heroin use has increased again, and yet the pharmacology of heroin is still poorly understood. After entering the body, heroin is rapidly deacetylated to 6-monoacetylmorphine (6-MAM), which is then deacetylated to morphine. Thus, drug addiction literature has long settled on the notion that heroin is little more than a pro-drug. In contrast to these former views, we will argue for a more complex interplay among heroin and its active metabolites: 6-MAM, morphine, and morphine-6-glucuronide (M6G). In particular, we propose that the complex temporal pattern of heroin effects results from the sequential, only partially overlapping, actions not only of 6-MAM, morphine, and M6G, but also of heroin per se, which, therefore, should not be seen as a mere brain-delivery system for its active metabolites. We will first review the literature concerning the pharmacokinetics and pharmacodynamics of heroin and its metabolites, then examine their neural and behavioral effects, and finally discuss the possible implications of these data for a better understanding of opioid reward and heroin addiction. By so doing we hope to highlight research topics to be investigated by future clinical and pre-clinical studies.

27 April 2021 in Journal of Medical Toxicology
Verified
Journal Article
Open access
PDF file
MMMichele Stanislaw Milella
Michele Stanislaw Milella
PBPaolo Boldrini
Paolo Boldrini
GVGabriella Vivino
Gabriella Vivino
MGMaria Caterina Grassi
Maria Caterina Grassi
Introduction Between early March 2020 and the end of May 2020, Italy issued strict measures to limit further spread of coronavirus disease 2019 (COVID-19) and became the first European country that imposed a lockdown on the population. The aim of this study was to assess the impact of these restricted conditions on the activity of the Poison Control Center (PCC) of Policlinico Umberto I Hospital-Sapienza University of Rome. Methods This was a retrospective analysis of calls received by the PCC during the lockdown period March 9, 2020 through May 31, 2020 compared to the same time period in year 2019 (reference). Results We observed a reduction in calls from hospitals and emergency departments and an increase in calls from private citizens about exposures to products or intoxications during the lockdown. There were increases in unintentional exposures and exposures to hand and surface sanitizers among household and cleaning products. There was a decrease in calls concerning medications, which were mostly from hospitals and emergency departments. We observed increases in exposures requiring clinical observations among adults and referral to the emergency department among pre-school children. Conclusions Public health protection measures against COVID-19 to improve hygiene and maintain clean environments can increase exposures to hazardous products in the domestic environment. We observed an increase in unintentional exposures to household and cleaning products during the lockdown and an increase in ED referrals for pre-school children compared to the previous year. Our data suggest the need for improvements in public campaigns that promote safer handling of household products and prevent unnecessary exposures during a lockdown. The public health promotion activity can benefit the community after the pandemic and prepare the community for lockdowns in the future.

1 September 2017 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
GBGiuseppe Bruno
Giuseppe Bruno
ASAnnalisa Saracino
Annalisa Saracino
LSLuigia Scudeller
Luigia Scudeller
CFClaudia Fabrizio
Claudia Fabrizio
RDRaffaele Dell’Acqua
Raffaele Dell’Acqua
GAGioacchino Angarano
Gioacchino Angarano
Direct-acting antiviral (DAA)-based treatment of hepatitis C virus (HCV) has been associated with high sustained virological response (SVR) rates and good tolerability in randomized clinical trials. This study was performed to assess the safety and effectiveness of DAAs in both HCV mono-infected and HIV/HCV co-infected patients. All consecutive HCV-infected patients, including HIV/HCV co-infected patients, receiving DAA-based treatment from February 2015 to September 2016 at the study clinic were included. Clinical, virological, and biochemical data were retrieved. The primary end-point was the SVR12 (HCV RNA undetectable 12 weeks after the end of treatment) is commonly used worldwide. The secondary end-point was the safety profile of DAAs during the treatment period. A total of 382 patients were included; 62 were HIV/HCV co-infected. Cirrhosis was found in 256 patients (67.4%). SVR12 was achieved in 365/382 (95.5%) individuals (58/62 HIV/HCV co-infected, 93.5%) in the intention-to-treat (ITT) analysis. A platelet count 20kPa (OR 3.05, 95% CI 1.03-8.96, p=0.04), and Model for End-Stage Liver Disease (MELD) score >10 (OR 5.27, 95% CI 1.16-23.8, p=0.03) were associated with lower SVR rates. On multivariate analysis, only genotype 3 infection remained a negative predictor of SVR (OR 21.6, 95% CI 3.81-123, p=0.001). Treatment discontinuation was observed in 10 subjects. Severe adverse events (SAEs) occurred in 17 patients (4.5%). High SVR12 rates were observed in both HCV mono-infected and HIV/HCV co-infected individuals. Overall, DAA-based treatment was safe and there were no differences in terms of SAEs and treatment discontinuation between the two groups.

9 March 2022 in Life
Verified
Journal Article
Open access
PDF file
Martina VincenziMartina Vincenzi
Martina Vincenzi
MMMichele Stanislaw Milella
Michele Stanislaw Milella
GDGinevra D'Ottavio
Ginevra D'Ottavio
DCDaniele Caprioli
Daniele Caprioli
Ingrid ReverteIngrid Reverte
Ingrid Reverte
DMDaniela Maftei
Daniela Maftei
Neuropathic pain (NP) originates from an injury or disease of the somatosensory nervous system. This heterogeneous origin and the possible association with other pathologies make the management of NP a real challenge. To date, there are no satisfactory treatments for this type of chronic pain. Even strong opioids, the gold-standard analgesics for nociceptive and cancer pain, display low efficacy and the paradoxical ability to exacerbate pain sensitivity in NP patients. Mounting evidence suggests that chemokine upregulation may be a common mechanism driving NP pathophysiology and chronic opioid use-related consequences (analgesic tolerance and hyperalgesia). Here, we first review preclinical studies on the role of chemokines and chemokine receptors in the development and maintenance of NP. Second, we examine the change in chemokine expression following chronic opioid use and the crosstalk between chemokine and opioid receptors. Then, we examine the effects of inhibiting specific chemokines or chemokine receptors as a strategy to increase opioid efficacy in NP. We conclude that strong opioids, along with drugs that block specific chemokine/chemokine receptor axis, might be the right compromise for a favorable risk/benefit ratio in NP management.

15 February 2024 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
MMMichele Stanislaw Milella
Michele Stanislaw Milella
LPLuisa Petraccia
Luisa Petraccia
FPFrancesca Pirelli
Francesca Pirelli
GFGiuseppe Foti
Giuseppe Foti
MSMaria Sapio
Maria Sapio
GVGabriella Vivino
Gabriella Vivino

28 July 2017 in Digestive and Liver Disease
Verified
Journal Article
Closed access
PDF file
RDRaffaele Dell’Acqua
Raffaele Dell’Acqua
GVGiuseppina De Vita
Giuseppina De Vita
APAndrea Procopio
Andrea Procopio
MMMichele Stanislaw Milella
Michele Stanislaw Milella
ASAnnalisa Saracino
Annalisa Saracino
GAGioacchino Angarano
Gioacchino Angarano